SCHEMBL23219192

SCHEMBL23219192

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C(=O)OC(C)(C)C)oc2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 3/20 0.40
HIF1A Q16665 1/20 0.37
KDM4E B2RXH2 6/20 0.37
ALDH1A1 P00352 5/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HPGD P15428 2/20 0.35
TP53 P04637 2/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
HSD17B10 Q99714 2/20 0.35
PTGS2 P35354 1/20 0.35
USP2 O75604 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852949 1.00 TSHR (0.40) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL23218440 0.92 TSHR (0.47) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL29592625 0.92 TSHR (0.47) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL29852809 0.89 SMN1; SMN2 (0.41) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL23218965 0.89 SMN1; SMN2 (0.41) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL29592645 0.89 KDM4E (0.42) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL23218326 0.89 KDM4E (0.42) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL23218650 0.88 TSHR (0.42) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL29852865 0.88 TSHR (0.42) TSHRLMNAMAPTHIF1AKDM4E
SCHEMBL23218789 0.86 TSHR (0.40) TSHRLMNAMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885LMNA 1698/4885MAPT 4793/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885LMNA 1844/4885MAPT 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.